Autonomous driving paper index
Autoinflammation with infantile enterocolitis associated with a novel CARD domain mutation in NLRC4: a case report and literature review
One-line summary
Background Autoinflammation with Infantile Enterocolitis (AIFEC, OMIM#616050) is a rare autosomal dominant autoinflammatory disorder caused by gain-of-function mutations in the NLRC4 gene.
Engineering notes
Laboratory investigations indicated significantly elevated inflammatory markers and endoscopic examination revealed multiple ulcers in the ileocolonic region.
Chinese explanation / 中文解读
中文解读待补充：本站会优先为端到端自动驾驶、BEV感知、3D目标检测、轨迹预测、路径规划、LiDAR感知等高价值论文补充中文说明。
Original abstract
Background Autoinflammation with Infantile Enterocolitis (AIFEC, OMIM#616050) is a rare autosomal dominant autoinflammatory disorder caused by gain-of-function mutations in the NLRC4 gene. The disease is characterized by recurrent systemic inflammatory flares with enterocolitis as a hallmark feature, though clinical presentations are broad and often nonspecific. Case presentation This report describes a noteworthy case of a pediatric patient with rare NLRC4 gene mutation leading to AIFEC. The patient was a 2-year-and-4-month-old female who presented with recurrent fever, chronic diarrhea, mucous bloody stools, and multi-system involvement. She had a history of multiple infections since early childhood. Laboratory investigations indicated significantly elevated inflammatory markers and endoscopic examination revealed multiple ulcers in the ileocolonic region. Whole-exome sequencing identified a de novo heterozygous mutation c.167A > G (p.His56Arg) in the CARD domain of NLRC4 gene, which was validated by Sanger sequencing and functionally assessed for pathogenicity. This specific gene locus mutation has not been reported in domestic or international literature to date. Clinical remission was achieved following infliximab treatment. Conclusion This case identifies a novel NLRC4 variant (c.167A > G, p.His56Arg) located in the CARD domain. Our findings expand the known mutational and phenotypic spectrum of AIFEC and add to emerging clinical evidence suggesting the potential utility of infliximab as a targeted therapeutic option for this rare autoinflammatory condition.
Links and sources
Need this topic turned into a technical roadmap?
Full Self Driving can prepare a custom autonomous driving literature review, code map, dataset map, and B2B technology assessment.
Request B2B research
Comments